Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Investing.com -- Corcept Therapeutics Incorporated (NASDAQ:CORT) stock climbed 5.8% following the presentation of positive data from its pivotal Phase 3 ROSELLA trial at the ASCO 2025 Annual Meeting. The trial evaluated relacorilant in combination with nab-paclitaxel for the treatment of platinum-resistant ovarian cancer.
The study met its primary endpoint of improved progression-free survival (PFS) as assessed by blinded independent central review (PFS-BICR), with patients receiving the relacorilant combination experiencing a 30% reduction in the risk of disease progression compared to those on nab-paclitaxel monotherapy. Median PFS-BICR was 6.5 months versus 5.5 months in the control group. The interim analysis also indicated a significant extension in overall survival (OS), with median OS reaching 16.0 months for the relacorilant group, in contrast to 11.5 months for the monotherapy group.
The safety profile of the relacorilant combination was comparable to that of the monotherapy, and the treatment was well-tolerated. Notably, patients treated with the combination therapy had a lower incidence of ascites and fewer abdominal paracenteses, suggesting an improved quality of life.
Dr. Alexander B. Olawaiye, the Principal Investigator of the ROSELLA trial, commented on the significance of the findings, stating, "Relacorilant plus nab-paclitaxel may provide a powerful tool for improving progression-free and overall survival in patients with this disease." The results, published in The Lancet, have set the stage for relacorilant to potentially become a new standard-of-care treatment for platinum-resistant ovarian cancer.
Corcept’s Chief Development Officer, Bill Guyer, expressed the company’s intent to expedite the treatment’s availability to patients, with regulatory applications in progress in the U.S. and Europe. The trial’s success also underscores the potential of modulating cortisol activity in patients with tumors expressing the glucocorticoid receptor.
The ROSELLA trial enrolled 381 patients across multiple countries and was conducted in collaboration with several global oncology groups. The dual primary endpoints of PFS-BICR and OS were considered positively met with the achievement of either endpoint.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.